CA2992483C - Quantitative peri-orbital application of ophthalmology drugs - Google Patents

Quantitative peri-orbital application of ophthalmology drugs Download PDF

Info

Publication number
CA2992483C
CA2992483C CA2992483A CA2992483A CA2992483C CA 2992483 C CA2992483 C CA 2992483C CA 2992483 A CA2992483 A CA 2992483A CA 2992483 A CA2992483 A CA 2992483A CA 2992483 C CA2992483 C CA 2992483C
Authority
CA
Canada
Prior art keywords
fluoro
carbonyl
amino
isopropyl ester
acid isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2992483A
Other languages
English (en)
French (fr)
Other versions
CA2992483A1 (en
Inventor
David Woodward
Weizhen Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenivision Inc
Original Assignee
Jenivision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenivision Inc filed Critical Jenivision Inc
Publication of CA2992483A1 publication Critical patent/CA2992483A1/en
Application granted granted Critical
Publication of CA2992483C publication Critical patent/CA2992483C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
CA2992483A 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs Active CA2992483C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/829,789 2015-08-19
US14/829,789 US9820954B2 (en) 2015-08-19 2015-08-19 Quantitative peri-orbital application of ophthalmology drugs
PCT/US2016/047230 WO2017031137A1 (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Publications (2)

Publication Number Publication Date
CA2992483A1 CA2992483A1 (en) 2017-02-23
CA2992483C true CA2992483C (en) 2024-03-19

Family

ID=58051248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2992483A Active CA2992483C (en) 2015-08-19 2016-08-17 Quantitative peri-orbital application of ophthalmology drugs

Country Status (9)

Country Link
US (1) US9820954B2 (enExample)
EP (1) EP3337474A4 (enExample)
JP (1) JP6924429B2 (enExample)
KR (1) KR102685479B1 (enExample)
CN (1) CN108135873A (enExample)
AU (1) AU2016308105B2 (enExample)
CA (1) CA2992483C (enExample)
MX (1) MX391627B (enExample)
WO (1) WO2017031137A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827225B2 (en) 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
KR20200037230A (ko) * 2017-06-30 2020-04-08 제니비젼 인크. 모발 성장용 제제
GB2597731A (en) * 2020-07-31 2022-02-09 Imperial College Innovations Ltd Preterm labour
WO2022170112A1 (en) * 2021-02-05 2022-08-11 Jenivision Inc. Compositions and methods for periorbital administration of ep2 receptor agonists
CA3212050A1 (en) * 2021-03-18 2022-09-22 Weizhen Wang Methods and compositions for treating eye diseases
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
CN116869991A (zh) * 2023-06-06 2023-10-13 南昌大学 柚皮素在制备治疗和/或预防眼部疾病的药物中的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3990444A (en) 1972-11-22 1976-11-09 Vial S.A.R.L. Blood transfusion apparatus
US4131115A (en) 1976-09-20 1978-12-26 Peng Sung S Eyelids-turning and eye-washing fixture
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
EP1723132A1 (en) 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
JP2007534384A (ja) 2004-04-23 2007-11-29 ミスティック ファーマシューティカルズ， インコーポレイテッド 複数の単位用量の薬物送達システム
US7226435B2 (en) 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
CA2611720A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
WO2007095486A1 (en) 2006-02-13 2007-08-23 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US8685439B2 (en) 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
CN101528211B (zh) * 2006-08-28 2012-10-10 千寿制药株式会社 眼用经皮吸收型制剂
ZA200902453B (en) * 2006-10-31 2010-07-28 Alcon Res Ltd PAI-1 binding modulators for the treatment of ocular disorders
ES2785056T3 (es) 2007-07-02 2020-10-05 Hoffmann La Roche Un dispositivo para la administración de fármacos
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
AU2008325214A1 (en) 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
EP2238101A2 (en) 2008-02-05 2010-10-13 Asterand Uk Limited Difluorobiphenylamide derivatives for the treatment of ocular hypertension
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP2493474B1 (en) 2009-10-30 2019-09-04 Intratus, Inc. Methods and compositions for sustained delivery of drugs
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
WO2011112713A2 (en) 2010-03-09 2011-09-15 Toxcure, Inc. Microneedle nasal delivery device
US9199066B2 (en) 2010-03-12 2015-12-01 Quattro Vascular Pte Ltd. Device and method for compartmental vessel treatment
US20120003296A1 (en) 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
GB2482691B (en) 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
US8900626B2 (en) 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
JP2014530177A (ja) * 2011-09-16 2014-11-17 フオベア・フアルマシユテイカル アニリン誘導体、それらの調製およびそれらの治療適用
US8785394B2 (en) 2011-11-15 2014-07-22 Allergan, Inc. Sustained action formulation of cyclosporin form 2
WO2014045300A2 (en) 2012-09-03 2014-03-27 Fdc Limited "topical drug delivery system"
CN203379477U (zh) 2012-12-14 2014-01-08 上海市第七人民医院 一种微针滚轮装置

Also Published As

Publication number Publication date
CA2992483A1 (en) 2017-02-23
JP2018528169A (ja) 2018-09-27
MX391627B (es) 2025-03-21
JP6924429B2 (ja) 2021-08-25
EP3337474A4 (en) 2019-04-10
AU2016308105A1 (en) 2018-02-15
KR102685479B1 (ko) 2024-07-15
CN108135873A (zh) 2018-06-08
US20170049734A1 (en) 2017-02-23
EP3337474A1 (en) 2018-06-27
AU2016308105B2 (en) 2021-05-27
MX2018001918A (es) 2018-11-09
US9820954B2 (en) 2017-11-21
KR20180042348A (ko) 2018-04-25
WO2017031137A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
AU2016308105B2 (en) Quantitative peri-orbital application of ophthalmology drugs
US8637054B2 (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
CN111867560B (zh) 包含噻吗洛尔的药物组合物
US10792288B2 (en) Preservative free brimonidine and timolol solutions
US20090318549A1 (en) Combination treatment of glaucoma
US11857537B2 (en) Use of prostacyclin antagonists for treating ocular surface nociception
CA2807081A1 (en) Preservative free bimatoprost and timolol solutions
JP2021191806A (ja) 眼科用清涼組成物
TWI852041B (zh) 採用長春西汀治療近視的方法
US20230372274A1 (en) Compositions and methods for periorbital administration of ep2 receptor agonists
IL191552A (en) Suxanimide derivatives for reducing ocular pressure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210526

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251211

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260325

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260401